Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 5/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596747 | 0.93 | HPGD (0.40) | HPGDHTR2AIDO1HTR1ASLC6A4 | |
| SCHEMBL6818762 | 0.79 | NOS3 (0.40) | HPGDHTR2AIDO1SLC6A4 | |
| SCHEMBL457099 | 0.79 | DPP4 (0.32) | HTR2AIDO1SLC6A4 | |
| SCHEMBL14850055 | 0.79 | — | — | |
| SCHEMBL2279322 | 0.79 | HTR2A (0.38) | HTR2AIDO1 | |
| SCHEMBL30945993 | 0.78 | IDO1 (0.46) | HTR2AIDO1HTR1ASLC6A4 | |
| SCHEMBL791872 | 0.78 | IDO1 (0.46) | HTR2AIDO1HTR1ASLC6A4 | |
| SCHEMBL5777589 | 0.77 | IDO1 (0.41) | HPGDHTR2AIDO1HTR1ASLC6A4 | |
| SCHEMBL1600326 | 0.76 | IDO1 (0.38) | HTR2AIDO1SLC6A4HDAC1 | |
| SCHEMBL1058869 | 0.76 | HTR2A (0.44) | HPGDHTR2AIDO1HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232390-B2 | Pentacyclic indole derivatives as antiviral agents | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2012-07-31 | — | — | US | disclosed |
| US-7989438-B2 | Therapeutic compounds | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-08-02 | — | — | US | disclosed |
| EP-2178886-A1 | MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2010-04-28 | — | — | EP | disclosed |
| EP-2178885-A1 | MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2010-04-28 | — | — | EP | disclosed |
| US-20100009959-A1 | Pentacyclic Indole Derivatives as Antiviral Agents | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-01-14 | — | — | US | disclosed |
| US-20090048239-A1 | Therapeutic compounds | MSD ITALIA S.R.L. (IT) | 2009-02-19 | — | — | US | disclosed |
| WO-2009010783-A1 | MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009010785-A1 | MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048239-A1 | Therapeutic compounds | RRP1B, RCE1, CTSZ | HPGD 2549/4885HTR2A 3606/4885IDO1 2560/4885 |
| US-20100009959-A1 | Pentacyclic Indole Derivatives as Antiviral Agents | IDO1, IDO2, ZC3HAV1 | HPGD 436/4885HTR2A 13/4885IDO1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.